Shire Mexico – Dr. Raul Vivar, Head of Mexico / Central America and…
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Today Shire provides treatments in the areas of Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine. The company has a portfolio of specialist therapies marketed in over 50 countries worldwide and offices in 29 countries. The company has been present in Mexico since 2008 focusing on lysosomal storage diseases therapies. In the near future the company plans to provide a therapeutic option to patients with hereditary angioedema and start its neuroscience business unit with a product indicated for ADHD (attention deficit hyperactivity disorder).
Address:
Shire Pharmaceuticals Mexico S.A. de C.V Av. Paseo de los Tamarindos 90, Torre 1, Piso 7 Col. Bosques de las Lomas, Del. Cuajimalpa C.P. 05120, México DF MEXICO Tel: +52 (55) 5081 0120 Website: www.shire.com.mx
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in Mexico where the state of Hidalgo has signed a deal with six Indian…
Pfizer, one of the world’s largest pharmaceutical companies, has been active in Mexico since 1951, and has been led in Mexico by Argentinean Constanza Losada as country president and CEO…
Recently appointed CEO and president for Pfizer Mexico, Constanza Losada, outlines the exciting challenge of taking on leadership for such an important affiliate during the COVID-19 pandemic and how Pfizer…
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and the impact of the country’s ongoing health reforms. In my experience,…
A compilation of the top 10 pharmaceutical companies in the Mexican pharmaceutical market based on IQVIA data from February MAT 2020. Four of the top ten companies are Mexican: PISA,…
UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region…
Americo Garcia oversees Latin American operations for Canadian generics player Apotex. He outlines the firm’s impressive growth in the region in recent years – expanding both in terms of portfolio…
Inosan Biopharma General Manager Juan Lopez de Silanes outlines the Mexican family company’s recent milestones, including an impressive internationalisation push in the Middle East & Africa Region, how demand for…
Sara Montero, managing director of Lundbeck Mexico, Central America and Andean countries since January 2020, explains her key priorities and the importance of the region for Lundbeck, highlights the current…
Mauricio Guizar, newly appointed general manager of Ipsen Mexico since October 2019, shares his first impression of the French specialty care player’s operations in Mexico, the significance of being the…
Francisco Kuri Breña, director of new developments at local Mexican player Landsteiner, shares the company’s existing positioning as one of the top 10 suppliers of generic medicines to the Mexican…
CP Maria del Socorro España Lomeli, executive director of the Mexican generics industry association ANAFAM, discusses the challenges with regard to the ‘new rules of the game’ in Mexico’s healthcare…
See our Cookie Privacy Policy Here
